Medtronic Raises 2027 Forecasts Amid Heart Device Surge

Medtronic has revised its fiscal 2027 financial projections upward, driven by a surge in demand for its heart devices used in complex cardiovascular procedures. The company now anticipates annual organic revenue growth between 7.25% and 7.75%, an increase from its previous estimate of 6.75% to 7.25%. This adjustment reflects the broader adoption of advanced medical technologies and a robust demand for surgical procedures.

Investments in Heart and Robotics Technology

In a move to bolster its portfolio, Medtronic announced an $80 million investment in Pi-Cardia, a heart-valve repair device maker, with an option to acquire the company for $210 million. Additionally, Medtronic has invested $700 million in Cornerstone Robotics, securing rights to distribute a robotic surgical device in select markets outside the United States. CEO Geoff Martha highlighted the strategic importance of these investments, noting the low penetration of soft tissue robotic surgery in emerging markets and the complementary nature of Cornerstone's Sentire device to Medtronic's existing Hugo system.

Financial Performance and Market Dynamics

Medtronic's financial outlook also benefited from tariff refunds received during the quarter, though these are not factored into future projections. The company's cardiovascular segment saw a significant 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was largely driven by an 88% surge in its pulsed field ablation portfolio, used to treat irregular heart rhythms.

For the quarter, Medtronic reported an adjusted per share profit of $1.45 on revenues of $9.76 billion, surpassing analyst expectations of $1.39 per share on $9.55 billion in sales, according to LSEG data. CFO Thierry Pieton emphasized the company's strategic focus on high-growth segments with large patient pools, supporting Medtronic's long-term growth objectives.

Outlook and Strategic Focus

CEO Geoff Martha expressed confidence in the company's performance, citing the strength across various business units and the increasing contributions from new growth platforms. Medtronic's focus on mergers and acquisitions aims to prioritize high-growth areas within the medtech sector that promise substantial patient engagement and market potential.

The company's strategic investments and revised forecasts underscore its commitment to advancing medical technology and expanding its global market presence, particularly in the cardiovascular and robotic surgery domains.